3.57
-1.12 (-23.90%)
| Previous Close | 4.69 |
| Volume | 239,371 |
| Price / Sales | 7.39 |
| Price / Book | 3.63 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,304.44% |
| Diluted EPS (TTM) | -2.34 |
| Total Debt/Equity (MRQ) | 64.25% |
| Current Ratio (MRQ) | 0.960 |
| Operating Cash Flow (TTM) | -15.17 M |
| Levered Free Cash Flow (TTM) | -11.89 M |
| Return on Assets (TTM) | -144.37% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | SeaStar Medical Holding Corpora | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.07 |
|
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 5.23% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |